Literature DB >> 33073649

A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.

Xueying Hou1,2, Yuelin Zhang2,3, Siyuan Han, Baoxian Hou4.   

Abstract

BACKGROUND: Prostate cancer (PC) is the most common non-cutaneous malignancy among men in the western world. However, heterogeneity remains a pressing clinical problem. RESEARCH DESIGN AND METHODS: The least absolute shrinkage and selection operator (LASSO) was used to screen the prognostic signature. Weighted correlation network analysis (WGCNA) was used to identify the target genes associated with high-risk characteristics. Gene set enrichment analysis was used to suggest the molecular mechanism of MYBL2 in PC. In addition, in vitro experiments were carried out to validate the role of MYBL2 in PC.
RESULTS: Ten DNA methylation sites were selected as the prognostic signature. A high expression of MYBL2 was associated with a poor prognosis in PC patients. The effect of MYBL2 in PC was related to KRAS, AKT, IL21, and ATM. MYBL2 facilitates the proliferation, migration, invasion, and metastasis of PC cells.
CONCLUSIONS: We developed a DNA methylation 10-CpG prognostic signature to predict the prognosis of PC patients. And the high expression of MYBL2 in PC may be related to poor prognosis.

Entities:  

Keywords:  DNA methylation; LASSO; TCGA; WGCNA; multiple omics

Mesh:

Substances:

Year:  2020        PMID: 33073649     DOI: 10.1080/14737140.2020.1838280

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

1.  MYBL2 accelerates epithelial-mesenchymal transition and hepatoblastoma metastasis via the Smad/SNAI1 pathway.

Authors:  Meng Wei; Ran Yang; Mujie Ye; Yong Zhan; Baihui Liu; Lingdu Meng; Lulu Xie; Min Du; Junfeng Wang; Runnan Gao; Deqian Chen; Rui Dong; Kuiran Dong
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3.

Authors:  Wei Liu; Dexin Shen; Lingao Ju; Renjie Zhang; Wenzhi Du; Wan Jin; Kangping Xiong; Gang Wang; Kaiyu Qian; Yi Zhang; Yu Xiao; Xinghuan Wang
Journal:  Oncogene       Date:  2022-09-07       Impact factor: 8.756

3.  Comprehensive Analysis of the Expression and Prognosis for the DREAM Complex in Human Cancers.

Authors:  Lulu Wang; Xiaowei Liu
Journal:  Front Genet       Date:  2022-05-12       Impact factor: 4.772

4.  MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.

Authors:  Meng Jiao; Facai Zhang; Wei Teng; Chengjun Zhou
Journal:  Int J Gen Med       Date:  2022-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.